AARDS IS PLEASED TO ANNOUNCE THAT THE CLINICAL RESULTS FROM THE COVID LONG HAULER STUDY PERFORMED LAST YEAR HAS BEEN PUBLISHED
We are excited to see that the patients who were on the actual treatment arm with Leronlimab appear to have significant improvement. Also noted was that there was an apparent benefit on the function of their immune system. We once more would like to thank the individuals who participated in the study and our staff who conducted the study. Finally, we continue to offer novel treatments and research study opportunities for the Covid Long Hauler population with the hope that we can provide some benefit and support for this very difficult medical problem.
About Norman B. Gaylis, M.D.
Norman B. Gaylis is recognized as one of the country’s leaders in the field of arthritis and rheumatic diseases. He is board-certified in Internal Medicine and Rheumatology and has been a practicing Rheumatologist in the greater Miami area for more than 35 years.
Dr. Gaylis was born in Johannesburg, South Africa and completed his training as a rheumatologist at the University of Miami where he served on the clinical faculty for many years. Dr. Gaylis has presented numerous scientific papers and has conducted medical meetings around the United States and internationally. He is the author of multiple peer reviewed articles, in particular on the subjects of rheumatoid arthritis, magnetic resonance imaging in rheumatology and other rheumatic disorders.
In addition to his clinical practice, he was the past Medical Director for the Rheumatology division at Cardinal Health and is a speaker and consultant for numerous pharmaceutical companies. Dr. Gaylis is the Medical Director of AARDS Research, Inc., a clinical research organization specializing in clinical research trials for autoimmune diseases and the Medial Director of Infusion and Immunotherapy Center of South Florida (IIC.)
He has been a Principal Investigator in over 150 clinical trials for new pharmaceutical products for the treatment of Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus, Lupus Nephritis, Gout, and Sjogren’s syndrome.
The recipient of many awards and honors, Dr. Gaylis is an active member of the American College of Rheumatology (ACR) and is currently serving as a Board Member. Dr. Gaylis is a 2017 recipient of the Master of the ACR Designation. Recognition as a Master is one of the highest honors that the College bestows on its distinguished members.
He is a past Board member of the Rheumatology Research Foundation. As part of his commitment to clinical research, he has recently established an endowment (Norman B Gaylis, MD Research Award for Rheumatologists in Community Practice) for the Rheumatology Research Foundation to award annually for the exclusive support of research by rheumatologists in clinical practice. He strongly believes in the benefits of clinical research breaking the ground for new treatments and the viability of rheumatologists in the future of healthcare.
He is one of the founders and is a Past President of the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR). He is also a past president of the Florida Society of Rheumatology.
He has been featured in the Wall Street Journal, on multiple television news shows, and for many years was also the host of HEALTH TALK, a medical talk show on the radio in South Florida. He is also on the Editorial Board of Rheumatology News for which he has contributed numerous articles.
COVID LONG HAULER TRIAL
Using a Non-Pharmaceutical Dietary Supplement
*Limited to 100 people
We are excited to announce that AARDS Research will be conducting a trial using an all natural dietary supplement to assist with reducing the signs and symptoms of COVID long hauler.
AARDS Research has been performing clinical research for the past 35 years and has conducted over 100 clinical trials. We have recently completed a long hauler trial using the medication leronlimab. Founded by Dr. Norman Gaylis, who has been treating long haulers since the beginning of the pandemic, the study will be conducted by the staff at AARDS Research.
For further details and the list of all ingredients please click here.
The dietary supplement (nutraceutical) is the result of research of scientists from the University of Tel Aviv. Based on their medical experience and Dr. Norman Gaylis’s clinical experience in treating long haulers, this dietary supplement has been formulated. This dietary supplement is not meant to treat, cure, or diagnose any disease, but rather help in reducing the signs and symptoms long haulers are experiencing. The ingredients contained in the dietary supplement are made from all natural ingredients and are all GRAS (generally recognized as safe) approved. A complete list of the ingredients can be found on the attached link. Participants are encouraged to check with their family physician before starting the product.
Participation in the research trial is voluntary and participants must show proof of a previous positive COVID test and be experiencing symptoms of COVID for greater than 12 weeks. Participants must be greater than 18 years of age and may not be pregnant or breastfeeding. The trial will be 6 weeks in duration and participants will be asked to take a dietary supplement (nutraceutical) containing all natural ingredients twice daily and then complete an on-line survey every two weeks describing any changes in their COVID symptoms. The participant will receive the product every two weeks in the mail after completing the on-line survey. This will continue for a period of six weeks.
An Informed Consent must be signed by the participant before starting the study and participants are encouraged to read the Informed Consent completely before signing.
If you would like more information about participation in this study, you may contact the Research Department at 305-504-8536.
A member of the research staff can answer all of your questions.
If you are ready to participate, complete the Contact form and the Informed Consent page will be send and must be sign electronically .
You must then forward your proof of a previous positive COVID test to firstname.lastname@example.org.
*This product is not used to diagnose, treat or cure any disease.
Abby sharing her story in Live on CNN with Norman B. Gaylis, MD
"I'm almost nine months into this nightmare that I'm living. I've seen 40 doctors, I've been to the ER five times, I've been hospitalized twice, and I still don't have answers." Abby Gresko Barclay has had coronavirus symptoms for nine months.
Michael Jaar sharing his story on Local 10 with Norman B. Gaylis, MD
Michael Jaar suffered Swelling joints after being affected by Covid19 . Dr Gaylis find a treatment for his long hauler symptoms
Long haulers syndrome can affect more than 10% of COVID-19 patients, including those with either serious or mild symptoms during their initial period with the virus.
Local drug trial provides hope for COVID ‘long-haulers’
Some COVID patients still have symptoms for months even after they recover. It’s called COVID long-haul syndrome. A South Florida doctor is overseeing a new study that’s providing hope for “long-haulers.”
Dr. Norman Gaylis with Arthritis & Rheumatic Disease Specialties is now conducting a trial, approved by the Food and Drug Administration, with a drug called leronlimab. He’s hoping it will ease the suffering of “long-haulers.”
Dr. Norman Gaylis: “We are very excited to give our patients this opportunity to see whether this drug is going to reduce their symptoms, because their symptoms are literally debilitating. This is a so-called double blind placebo study, which means we don’t know who’s getting drug and who’s getting placebo.”
Local drug trial shows sign of hope for COVID ‘long-haulers’
People who continue to suffer debilitating symptoms after recovering from COVID-19 have what’s called COVID long-haul syndrome. But now, a South Florida doctor is giving them a healthy dose of hope after an eight-week clinical trial. 7’s Kevin Ozebek has the story.
This is Eli Musser in early March.
He was weak and had trouble walking. He had lingering COVID symptoms, even though he caught the virus almost a year earlier.
Eli Musser, back in March: “It just feels like I weigh a thousand pounds, and shortness of breath, absolutely debilitating.”
Eli's final visit with Dr. Gaylis
We are anticipating that the double blinded study using leronlimab will be unblinded within the next week. Eli, and the other participants will find out which treatment arm they received. We look forward to the next study that will use the same treatment leronlimab with different dosages.
Long Hauler Study Follow-Up
Covid-19 Long Hauler Clinical Trial Preliminary Results Are Released By CytoDyn
Potential Treatment For A Covid-19 Long Hauler Syndrome
Preliminary results of drug study for Covid-19 Long Haulers are promising. Thanks, @WPLGLocal10 for featuring the preliminary results of the clinical trial for Covid Long Haulers
ARE YOU A COVID19 LONG HAULER?
In some patients the effects of COVID-19 linger after the infection is no longer active. These patients suffering from lingering symptoms of the virus are called long haulers. They have in theory recovered from the worst impacts of COVID-19 and some may have tested negative for the antibodies; however, they are still symptomatic. They may have lingering symptoms or have developed new complaints which range from mild to debilitating. The most common long hauler symptoms include:
Shortness of breath
Loss of taste or smell
COVID19 LONG HAULER CLINIC AT AARDS
Most of the symptoms of COVID-19 are a result of an overactive immune system
response resulting in cytokines ( which are the body’s anti-inflammatory cells) to indiscriminately cause inflammation and problems with many or all of the organs in the body. This is the same mechanism that occurs in many autoimmune disorders such as systemic lupus erythematosus (SLE), vasculitis, rheumatoid arthritis and several other conditions which are routinely treated by a rheumatologist such as Dr. Norman Gaylis and his associates, using multiple treatments ranging from corticosteroids to biologic drugs.
Based on our experience at AARDS of this immune inflammatory behavior, we have been treating several COVID-19 “long haul” patients with a similar approach with the treatment choices tailored to the particular presentation of symptoms of each patient. We are also optimistic that in the near future we will be able to have the opportunity to start treating long haul patients with a unique monoclonal antibody though a clinical research study which is currently under review by the FDA.
PRE-SCREENING LONG HAULERS
We will be participating in the near future in a clinical research trial using leronlimab, which is a unique monoclonal antibody. We are pre-screening patients for this long hauler clinical trial while we await the FDA approval of the protocol for use with the drug.
If you are accepted into the clinical trial by meeting all of the Inclusion/Exclusion criteria, there will be no cost to the patient for participation. PARTICIPANT MUST BE LOCATED IN MIAMI, FLORIDA .
Please call us at 305-405-1590 for more information or to make an appointment.
FOLLOW US @COVID19LONGHAULERCLINIC
CALL US AT 305-405-1590
2801 NE 213th St. Suite 801
Aventura, FL 33180
WHAT OUR PATIENTS SAYS
"I notice a big difference in energy and mental clarity and I feel 100% back to normal at this point"
"2 years of symptoms, pain and dysfunction, are resolving. Most of my pain is gone, energy level greatly improved and fog reduced"